Agiliti downgraded to Neutral at BofA on lower visibility

As previously reported, BofA analyst Kevin Fischbeck downgraded Agiliti to Neutral from Buy with a $19 price target. Agiliti does not appear to benefit from the multi-year repricing tailwinds that is driving his more bullish view for other healthcare providers he covers heading into 2024, leading him to see a balanced risk/reward and prefer other names in the space, Fischbeck tells investors. With Agiliti having cut fiscal year guidance twice after missing in both Q2 and Q3, he sees limited visibility, Fischbeck added.